Immunis Chairman Dr. Hans Keirstead Visits His Holiness the Dalai Lama

IRVINE, Calif.–(BUSINESS WIRE)–#DalaiLama–Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman, renowned neuroscientist Hans Keirstead, Ph.D., visited the Dalai Lama again this past week in His home in Dharamsala, India. The Dalai Lama remains a symbol of the unifying philosophy of Buddhism, where He is respected internationally as an educator of harmony and happiness for humanity.

Dr. Keirstead and His Holiness share a passion to explore the scientific evidence of consciousness and the location of consciousness, a project which burgeoned 3 years ago during Dr. Keirstead�s first visit with His Holiness. To further this project, Dr. Keirstead and His Holiness welcomed five other internationally renowned thought leaders to discuss perspectives from multiple scientific domains. The experts and their domains included His Holiness the Dalai Lama (reincarnation), Hans S. Keirstead, Ph.D. (neuroscience), Sir Roger Penrose, Ph.D. (quantum physics), Peter Brooke Cadogan Fenwick, M.D. (medically recorded near-death experiences), Adrian Kent, Ph.D. (theoretical physics), Olaf Blanke, M.D./Ph.D. (medically recorded out-of-body experiences) and Wayne Jonas, M.D. (mind-spirit benefit to physiology). They explored whether scientific evidence from these various domains could support a model of consciousness, and whether consciousness could reside outside of the human body.

“Given recent technical advances, the time is right for a multidisciplinary scientific exploration of consciousness and its location,” says Dr. Keirstead, “The results of this project will have a profound effect on human behavior.”

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The STEM product line leverages Immunis’ leading-edge capabilities in stem cell technologies to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ IMM01-STEM Phase 1/2a trial please visit: www.immunisbiomedical.com

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Contacts

contact@immunisbiomedical.com